Report cover image

Chronic Obstructive Pulmonary Disease (COPD) Market Growth, Size, Trends Analysis- By Type, By Treatment Type, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2033

Publisher SPER Market Research Pvt. Ltd.
Published Nov 08, 2024
Length 235 Pages
SKU # SPER19396719

Description

Chronic Obstructive Pulmonary Disease (COPD) Market Growth, Size, Trends Analysis- By Type, By Treatment Type, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2033


Chronic Obstructive Pulmonary Disease (COPD) Market Introduction and Overview

According to SPER Market Research, ‘Global Chronic Obstructive Pulmonary Disease (COPD) Market Size- By Type, By Treatment Type, By End User – Regional Outlook, Competitive Strategies and Segment Forecast to 2033’ states that the Global Chronic Obstructive Pulmonary Disease (COPD) Market is estimated to reach USD 33.31 billion by 2033 with a CAGR of 4.68%.

Chronic obstructive pulmonary disease (COPD), a degenerative lung disease, is characterized by persistent respiratory symptoms and airflow restriction. It encompasses conditions like emphysema and chronic bronchitis that are primarily caused by long-term exposure to harmful gases or particles, most commonly by smoking. Coughing, wheezing, and increased mucus production are all symptoms of the illness’s inflammation and destruction to the lung tissue and airways, which makes breathing difficult.

The global market for chronic obstructive pulmonary disease (COPD) has been significantly impacted by the COVID-19 pandemic, presenting both potential and challenges. Because of their underlying respiratory disorders, those with COPD were more vulnerable during the pandemic, leading to an increase in hospitalizations and a focus on respiratory health. Prioritizing COVID-19 responses often caused healthcare systems to disrupt regular care and management of COPD, which impacted patients’ access to medications and made their illnesses worse.

Scope of the report:

Report Metric Details
Market size available for years 2020-2033
Base year considered 2023
Forecast period 2024-2033
Segments covered By Type, By Treatment Type, By End User
Regions covered North America, Asia-Pacific, Latin America, Middle East & Africa and Europe
Companies Covered Pfizer Inc, Merck & Co., Inc, Novartis AG, AstraZeneca, GlaxoSmithKline plc, Roche (F. Hoffmann-La Roche Ltd, Switzerland), Abbott, Boehringer Ingelheim International GmbH, Biogen, Teva Pharmaceutical Industries Ltd, Others.

Chronic Obstructive Pulmonary Disease (COPD) Market Segmentation:

By Type: Based on the Type, Global Chronic Obstructive Pulmonary Disease (COPD) Market is segmented as; Chronic Bronchitis, Emphysema.

By Treatment Type: Based on the Treatment Type, Global Chronic Obstructive Pulmonary Disease (COPD) Market is segmented as; Bronchodilator monotherapy, short-acting beta2-agonists (SABAs), long-acting beta2-agonists (LABAs), anti-cholinergic agents, anti-inflammatory drugs, oral and inhaled corticosteroids, anti-leukotrienes, surgery, lung volume reduction surgery (LVRS), lung transplant, bullectomy and others.

By End User: Based on the End User, Global Chronic Obstructive Pulmonary Disease (COPD) Market is segmented as; Hospitals, Homecare Settings, Clinics, Others

By Region: This research also include data for North America, Europe, Asia-Pacific Middle East & Africa and South America.

Table of Contents

235 Pages
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPER’s internal database
2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
4.2. COVID-19 Impacts of the Global Chronic Obstructive Pulmonary Disease (COPD) Market.
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER’s Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Chronic Obstructive Pulmonary Disease (COPD) Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Chronic Obstructive Pulmonary Disease (COPD) Market
7. Global Chronic Obstructive Pulmonary Disease (COPD) Market, By Type (USD Million) 2020-2033
7.1. Global Chronic Obstructive Pulmonary Disease (COPD) Market Size, Share and Forecast, By Type, 2020-2026
7.2. Global Chronic Obstructive Pulmonary Disease (COPD) Market Size, Share and Forecast, By Type, 2027-2033
7.3. Chronic Bronchitis
7.4. Emphysema
8. Global Chronic Obstructive Pulmonary Disease (COPD) Market, By Treatment Type (USD Million) 2020-2033
8.1. Global Chronic Obstructive Pulmonary Disease (COPD) Market Size, Share and Forecast, By Treatment Type, 2020-2026
8.2. Global Chronic Obstructive Pulmonary Disease (COPD) Market Size, Share and Forecast, By Treatment Type, 2027-2033
8.3. Drugs
8.4. Bronchodilator Monotherapy
8.5. Short-Acting Beta2-Agonists (SABAS)
8.6. Long-Acting Beta2-Agonists (LABAS)
8.7. Anti-Cholinergic Agents
8.8. Anti-Inflammatory Drugs
8.9. Oral And Inhaled Corticosteroids
8.10. Anti-Leukotrienes
8.11. Surgery
8.12. Lung Volume Reduction Surgery (LVRS)
8.13. Lung Transplant, Bullectomy
8.14. Others
9. Global Chronic Obstructive Pulmonary Disease (COPD) Market, By End User (USD Million) 2020-2033
9.1. Global Chronic Obstructive Pulmonary Disease (COPD) Market Size, Share and Forecast, By End User, 2020-2026
9.2. Global Chronic Obstructive Pulmonary Disease (COPD) Market Size, Share and Forecast, By End User, 2027-2033
9.3. Hospitals
9.4. Homecare Settings
9.5. Clinics
9.6. Others
10. Global Chronic Obstructive Pulmonary Disease (COPD) Market Forecast, 2020-2033 (USD Million)
10.1. Global Chronic Obstructive Pulmonary Disease (COPD) Market Size and Market Share
11. Global Chronic Obstructive Pulmonary Disease (COPD) Market, By Region, 2020-2033 (USD Million)
11.1. Global Chronic Obstructive Pulmonary Disease (COPD) Market Size and Market Share By Region (2020-2026)
11.2. Global Chronic Obstructive Pulmonary Disease (COPD) Market Size and Market Share By Region (2027-2033)
11.3. Asia-Pacific
11.3.1. Australia
11.3.2. China
11.3.3. India
11.3.4. Japan
11.3.5. South Korea
11.3.6. Rest of Asia-Pacific
11.4. Europe
11.4.1. France
11.4.2. Germany
11.4.3. Italy
11.4.4. Spain
11.4.5. United Kingdom
11.4.6. Rest of Europe
11.5. Middle East and Africa
11.5.1. Kingdom of Saudi Arabia
11.5.2. United Arab Emirates
11.5.3. Qatar
11.5.4. South Africa
11.5.5. Egypt
11.5.6. Morocco
11.5.7. Nigeria
11.5.8. Rest of Middle-East and Africa
11.6. North America
11.6.1. Canada
11.6.2. Mexico
11.6.3. United States
11.7. Latin America
11.7.1. Argentina
11.7.2. Brazil
11.7.3. Rest of Latin America
12. Company Profile
12.1. Pfizer Inc
12.1.1. Company details
12.1.2. Financial outlook
12.1.3. Product summary
12.1.4. Recent developments
12.2. Merck & Co., Inc
12.2.1. Company details
12.2.2. Financial outlook
12.2.3. Product summary
12.2.4. Recent developments
12.3. Novartis AG
12.3.1. Company details
12.3.2. Financial outlook
12.3.3. Product summary
12.3.4. Recent developments
12.4. AstraZeneca
12.4.1. Company details
12.4.2. Financial outlook
12.4.3. Product summary
12.4.4. Recent developments
12.5. GlaxoSmithKline plc
12.5.1. Company details
12.5.2. Financial outlook
12.5.3. Product summary
12.5.4. Recent developments
12.6. Roche (F. Hoffmann-La Roche Ltd, Switzerland)
12.6.1. Company details
12.6.2. Financial outlook
12.6.3. Product summary
12.6.4. Recent developments
12.7. Abbott
12.7.1. Company details
12.7.2. Financial outlook
12.7.3. Product summary
12.7.4. Recent developments
12.8. Boehringer Ingelheim International GmbH
12.8.1. Company details
12.8.2. Financial outlook
12.8.3. Product summary
12.8.4. Recent developments
12.9. Biogen
12.9.1. Company details
12.9.2. Financial outlook
12.9.3. Product summary
12.9.4. Recent developments
12.10. Teva Pharmaceutical Industries Ltd
12.10.1. Company details
12.10.2. Financial outlook
12.10.3. Product summary
12.10.4. Recent developments
12.11. Others
13. Conclusion
14. List of Abbreviations
15. Reference Links

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us